Last reviewed · How we verify
MM-II dose II
At a glance
| Generic name | MM-II dose II |
|---|---|
| Sponsor | Sun Pharmaceutical Industries Limited |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma (r/r MM) (PHASE1)
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NA)
- Ixazomib + Pomalidomide + Dexamethasone In MM (PHASE1, PHASE2)
- Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (PHASE2)
- COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide (PHASE1, PHASE2)
- Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma (PHASE2)
- TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck (NA)
- Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MM-II dose II CI brief — competitive landscape report
- MM-II dose II updates RSS · CI watch RSS
- Sun Pharmaceutical Industries Limited portfolio CI